GENE ONLINE|News &
Opinion
Blog

Deals
R&D
Merck Bets Big on Seattle Genetics for Two Oncology Drugs
2020-09-16
Gilead Strengthens its Oncology Portfolio with Acquisition of Immunomedics
2020-09-14
AI Drug Pioneer Recursion Pharma Raises $239 Million Led by Leaps By Bayer
2020-09-12
Cancer-Screening Startup GRAIL Files for IPO
2020-09-12
Google Backed Telehealth Company, Amwell Outlines Details of its Upcoming IPO
2020-09-10
Mylan Set to Expand Thrombosis Business in Europe with Aspen deal
2020-09-10
Encouraging Performance of Cardiovascular Drug Vindicates Novartis’ $9.7 Billion Buyout Deal
2020-09-06
Abbvie Places $2 Billion Bet on Flourishing Immunotherapy Area with this Oncology Partnership
2020-09-06
Australian Pharma Bags Government Funding to Fight Duchenne Muscular Dystrophy
2020-09-06
Spotlight: Cancer Drug Licensed from Danish Antibody Developer Continues to Reap Benefits for Janssen
2020-09-04
Gilead Adds Jounce to its Long List of Oncology Partnerships
2020-09-03
M&A
Nestlé to Acquire Aimmune Therapeutics in a $2.6 Billion Merger Agreement
2020-09-01
Nestlé to Acquire Aimmune Therapeutics in a $2.6 Billion Merger Agreement
2020-08-31
Freenome Receives $270 Million Funding for Early Cancer Detection
2020-08-27
UK Startup Biofidelity Ltd. Acquires $12 Million in Series A Financing
2020-08-23
1 41 42 43 44 45 47
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top